Lupin, Ceek ink Marketing Agreement to Improve OB/GYN, Patient Experience with Nella Products

Baltimore: Lupin Pharmaceuticals Inc., the U.S. based wholly-owned subsidiary of Lupin Limited, and Ceek Women's Health (Ceek) has announced an agreement to add Ceek's line of women's health products to Lupin's promotional offering in the United States, further enhancing the value that Lupin provides to OB/GYNs and their patients.

The promotional arrangement includes detailing and demonstration of Ceek's products, alongside Lupin's women's health flagship product, Solosec (secnidazole) 2g oral granules, indicated for the treatment of bacterial vaginosis (BV), a common vaginal infection in adult women. Solosec is a 5-nitroimidazole antimicrobial agent.

Offering the first innovative update to the vaginal speculum in nearly 150 years, the Nella NuSpec is the smarter reusable speculum. The NuSpec was developed after extensive prototyping and research to change the patient experience during gynecological exams. The VuSleeve and the VuLight are accessories to the speculum designed to provide easy visualization and access to the cervix. Ceek's product line is designed to improve the quality of care for all women as well as in specific segments, including adolescents, transgender patients, rape or trauma patients, post-menopausal women, and cancer survivors. Lupin will also be promoting another product currently in Ceek's pipeline later in the year.

"We are excited to add these innovative offerings to our customers and patients," said Jon Stelzmiller, President – Specialty, Lupin Pharmaceuticals, Inc. "This further emphasizes the Lupin commitment to women's health and to improving the patient and provider experience." Fahti Khosrowshahi, CEO of Ceek, added, "We are extremely excited to partner with Lupin. Lupin's integrity and commitment to women's health is unparalleled and this partnership is a pivotal milestone for Ceek as we transition to commercialization. The partnership with Lupin allows Ceek to launch our products nationally with a world-class field-force focused on OB/GYN providers."

Read also: Lupin Mexiletine Hydrochloride gets Orphan Drug Designation from USFDA